This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
AUA 2022 Bladder Cancer Forum
AUA 2022 Bladder Cancer Forum VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf
Details
Badrinath Konety and Wassim Kassouf discuss managing Bacillus Calmette–Guérin (BCG) toxicity and optimizing BCG therapy in bladder cancer with Wei Shen Tan. BCG toxicity can range from local bladder symptoms to systemic effects. Patient selection is crucial in reducing toxicity, avoiding BCG in cases of gross hematuria or symptomatic UTIs. Delaying BCG and using longer intervals between instillati...
Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley
Details
Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
The Controversy Over Radical Cystectomy for N1 and N2 Bladder Cancer: Experts Weigh In - Brant Inman & Yair Lotan
Details
Kamal Pohar moderates a conversation with Brant Inman and Yair Lotan. The experts delve into the role of radical cystectomy for clinical N1 or N2 bladder cancer. Dr. Inman advocates for cystectomy combined with lymph adenectomy after systemic therapy, emphasizing its potential for better patient outcomes. Dr. Lotan, however, raises concerns about the heterogeneity in node positivity and the limita...
The Impact of Variant Histology on the Management of Patients with Bladder Cancer - Mario Fernandez and Michael A. O’Donnell
Details
Michael O’Donnell and Mario Fernandez join Peter Black to discuss the impact of variant histology on managing patients with bladder cancer. The conversation begins with deciding when the evidence supports preserving the bladder vs. performing a cystectomy. Then the discussion moves to other treatment options, including how the BCG shortage has led to new treatment alternatives for micropapillary b...
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
Details
In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...
Do We Need to Perform Radical Cystectomy for Patients Who are cT0 After Neoadjuvant Chemotherapy? - Gary Steinberg & John Taylor
Details
The 2022 Annual Meeting of the American Urological Association (AUA) was host to The International Bladder Cancer Group (IBCG) AUA Bladder Cancer Forum which featured a case-based debate regarding the role of radical cystectomy in a patient who achieves a cT0 status after neoadjuvant chemotherapy. Drs. Gary Steinberg and John Taylor join Patrick Hensley providing highlights from their side of the...
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free